Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

Minimal residual disease (MRD) before myeloablative hematopoietic cell transplantation (HCT) is associated with adverse outcome in acute myeloid leukemia (AML) in first complete remission (CR1). To compare this association with that for patients in second complete remission (CR2) and to examine the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Walter, Roland B., Buckley, Sarah A., Pagel, John M., Wood, Brent L., Storer, Barry E., Sandmaier, Brenda M., Fang, Min, Gyurkocza, Boglarka, Delaney, Colleen, Radich, Jerald P., Estey, Elihu H., Appelbaum, Frederick R.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2013
Materias:
Transplantation
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3765060/
https://ncbi.nlm.nih.gov/pubmed/23847197
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-06-506725
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares